Skip to main content
SpringerLink
Log in

Pucotenlimab: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Pucotenlimab (Puyouheng™) is a humanised immunoglobulin (Ig) G4 monoclonal antibody (mAb) being developed by Lepu Biopharma for the treatment of solid tumours, including gastrointestinal cancer, metastatic melanoma, liver cancer, bladder cancer, non-small cell lung cancer and breast cancer. Pucotenlimab binds to PD-1 and blocks its interaction with its ligands, PD-L1 and PD-L2, thereby restoring the ability of immune cells to target cancer cells. In July 2022, pucotenlimab received conditional first approval in China for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours, including patients with advanced colorectal cancer who have experienced disease progression after previous therapy with fluorouracil, oxaliplatin and irinotecan, as well as patients with other advanced solid tumours who have experienced disease progression after previous first-line therapy and have no satisfactory treatment alternatives. In September 2022, pucotenlimab was approved in China for the treatment of unresectable or metastatic melanomas after the failure of previous systemic therapy. This article summarizes the milestones in the development of pucotenlimab leading to the first approval for the treatment of MSI-H/dMMR advanced solid tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jiang Y, Chen M, Nie H, et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111–22.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ai L, Chen J, Yan H, et al. Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy. Drug Des Devel Ther. 2020;14:3625–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Li H, van der Merwe PA, Sivakumar S. Biomarkers of response to PD-1 pathway blockade. Br J Cancer. 2022;126(12):1663–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Lepu Biopharma Co., Ltd. Conditional marketing approval obtained in China for Puyouheng (Pucotenlimab injection) for the treatment in high levels of microsatellite instability/deficient mismatch repair (MSI-H/DMMR) [media release]. 22 Jul 2022.  https://en.lepubiopharma.com/upload/listedco/listconews/sehk/2022/0722/2022072200169.pdf.

  5. Lepu Biopharma Co., Ltd., Hanx Biopharmaceuticals. Pucotenlimab: Chinese prescribing information. 2022.

  6. Lepu Biopharma Co., Ltd. Puyouheng (pucotenlimab injection) obtains approval for marketing with a new indication, breakthrough therapy designation granted by the CDE to MRG003 for the treatment of R/M NPC [media release]. 29 Sep 2022. https://www.acnnewswire.com/press-release/english/78266/

  7. Lepu Biopharma Co., Ltd. Post hearing information pack of Lepu Biopharma Co., Ltd. 2021. https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0223/sehk22020300054.pdf. Accessed 23 Aug 2022.

  8. Chi Med. Chi-Med enters into multiple collaborations to evaluate combinations of surufatinib and fruquintinib with PD-1 checkpoint inhibitors [media release]. 29 Nov 2018.  https://www.hutch-med.com/a181129/.

  9. Zhang J, Huang Y, Xi G, et al. HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties. MAbs. 2020;12(1):1724751.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Liu R, Li W, Meng Y, et al. Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors. Ther Adv Med Oncol. 2021;13:1–11.

    Article  Google Scholar 

  11. Huang J, Song Y, Luo S, et al. Efficacy of HX008 in high microsatellite instability/mismatch repair-deficient (MSI-H/dMMR) solid tumors: results from a multicenter phase II open-label study [abstract no. 2572]. J Clin Oncol. 2021;39(15 Suppl):2572.

    Article  Google Scholar 

  12. Song Y, Li N, Li Q, et al. HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. J Immunother Cancer. 2020;8(2): e001279.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Xu J, Xu N, Bai Y, et al. Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial. Oncoimmunology. 2020;10(1):1864908.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Zhang B, Huang J, Tang J, et al. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial. J Immunother Cancer. 2021;9(4): e002224.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lian B, Chen Y, Wu D, et al. Safety and efficacy of HX008: A humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma-A single-arm, multicenter, phase II study [abstract no. 9554]. J Clin Oncol. 2021;39(15 Suppl):9554.

    Article  Google Scholar 

  16. Hu XC, Cao J, Wang BY, et al. Phase 1b clinical trial of HX008, a novel anti-PD-1 monoclonal antibody, Combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer [abstract no. PS12-11]. Cancer Res. 2021;81(4 Suppl):PS12-11.

    Article  Google Scholar 

  17. Cao J, Hu XC, Wang BY, et al. Update survival of phase 1b clinical trial of HX008, a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer [abstract no. PO60]. Breast. 2021;59(Suppl 1):S48.

    Article  Google Scholar 

  18. Huang J, Luo S, Chen P, et al. A randomized, double-blinded, placebo-controlled phase III trial of HX008 plus irinotecan as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma [abstract no. 1439TiP and poster]. Ann Oncol. 2021;32(Suppl 5):S1075.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Sohita Dhillon

Authors
  1. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohita Dhillon.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 581 KB)

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhillon, S. Pucotenlimab: First Approval. Drugs 82, 1557–1564 (2022). https://doi.org/10.1007/s40265-022-01787-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-022-01787-z

Search

Navigation